Elkhorn Partners Limited Partnership Takes Position in CRISPR Therapeutics AG (NASDAQ:CRSP)

Elkhorn Partners Limited Partnership bought a new stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 1,000 shares of the company’s stock, valued at approximately $54,000.

A number of other large investors have also recently made changes to their positions in the stock. Riggs Asset Managment Co. Inc. raised its holdings in shares of CRISPR Therapeutics by 66.7% in the first quarter. Riggs Asset Managment Co. Inc. now owns 500 shares of the company’s stock valued at $34,000 after acquiring an additional 200 shares in the last quarter. SFE Investment Counsel lifted its position in shares of CRISPR Therapeutics by 3.6% during the second quarter. SFE Investment Counsel now owns 5,846 shares of the company’s stock valued at $316,000 after buying an additional 203 shares during the last quarter. Orion Capital Management LLC lifted its position in shares of CRISPR Therapeutics by 44.0% during the first quarter. Orion Capital Management LLC now owns 720 shares of the company’s stock valued at $49,000 after buying an additional 220 shares during the last quarter. National Bank of Canada FI lifted its position in shares of CRISPR Therapeutics by 35.0% during the second quarter. National Bank of Canada FI now owns 848 shares of the company’s stock valued at $46,000 after buying an additional 220 shares during the last quarter. Finally, Larson Financial Group LLC lifted its position in shares of CRISPR Therapeutics by 95.5% during the second quarter. Larson Financial Group LLC now owns 565 shares of the company’s stock valued at $31,000 after buying an additional 276 shares during the last quarter. 69.20% of the stock is owned by hedge funds and other institutional investors.

CRISPR Therapeutics Price Performance

Shares of NASDAQ CRSP opened at $49.87 on Wednesday. The stock has a market capitalization of $4.23 billion, a price-to-earnings ratio of -18.33 and a beta of 1.68. CRISPR Therapeutics AG has a 12 month low of $37.55 and a 12 month high of $91.10. The firm’s 50 day simple moving average is $50.91 and its 200-day simple moving average is $57.51.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Monday, August 5th. The company reported ($1.49) EPS for the quarter, missing analysts’ consensus estimates of ($1.43) by ($0.06). The firm had revenue of $0.52 million for the quarter, compared to analyst estimates of $12.31 million. CRISPR Therapeutics’s revenue for the quarter was down 99.3% on a year-over-year basis. During the same quarter last year, the firm earned ($0.98) earnings per share. Analysts anticipate that CRISPR Therapeutics AG will post -5.6 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have commented on CRSP shares. Chardan Capital decreased their price target on shares of CRISPR Therapeutics from $112.00 to $94.00 and set a “buy” rating for the company in a research report on Tuesday, August 6th. Cantor Fitzgerald reissued a “neutral” rating on shares of CRISPR Therapeutics in a research report on Thursday, August 8th. Needham & Company LLC decreased their price target on shares of CRISPR Therapeutics from $88.00 to $84.00 and set a “buy” rating for the company in a research report on Tuesday, August 6th. Rodman & Renshaw assumed coverage on shares of CRISPR Therapeutics in a research report on Friday, August 2nd. They issued a “buy” rating and a $90.00 price objective for the company. Finally, StockNews.com raised shares of CRISPR Therapeutics to a “sell” rating in a research report on Friday, August 16th. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $75.63.

Insider Activity at CRISPR Therapeutics

In related news, COO Julianne Bruno sold 3,366 shares of CRISPR Therapeutics stock in a transaction on Friday, June 21st. The shares were sold at an average price of $56.09, for a total value of $188,798.94. Following the sale, the chief operating officer now owns 6,745 shares of the company’s stock, valued at approximately $378,327.05. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 4.10% of the stock is owned by corporate insiders.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.